While the chief executive of Eli Lilly may lament the UK’s drug prices (UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker, 24 September), the NHS should celebrate them. The system put in place for evaluating the cost-effectiveness of new drugs is respected the world over and is successful in applying the principle that funding a new product should not damage the NHS as a whole. This principle of cost-effectiveness has led to widespread price reductions for the NHS that have allowed the service as a whole to benefit.
The chief executive of Eli Lilly links the recent pausing or cancelling of pharmaceutical industry investments in the UK to drug pricing here, when these are down to the drug companies’ desperation to kowtow to Donald Trump.
